Stangier J - Search Results

1

Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

Stangier J, Clemens A. Stangier J, et al. Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:9S-16S. doi: 10.1177/1076029609343004. Epub 2009 Aug 19. Clin Appl Thromb Hemost. 2009. PMID: 19696042 Free article. Review.

2

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. van Ryn J, et al. Among authors: stangier j. Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29. Thromb Haemost. 2010. PMID: 20352166 Review.

3

Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Eisert WG, et al. Among authors: stangier j. Arterioscler Thromb Vasc Biol. 2010 Oct;30(10):1885-9. doi: 10.1161/ATVBAHA.110.203604. Epub 2010 Jul 29. Arterioscler Thromb Vasc Biol. 2010. PMID: 20671233 Review.

4

Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate.

Härtter S, Yamamura N, Stangier J, Reilly PA, Clemens A. Härtter S, et al. Among authors: stangier j. Thromb Haemost. 2012 Feb;107(2):260-9. doi: 10.1160/TH11-08-0551. Epub 2011 Dec 21. Thromb Haemost. 2012. PMID: 22186806

5

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.

Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, Lehr T. Clemens A, et al. Among authors: stangier j. Curr Med Res Opin. 2012 Feb;28(2):195-201. doi: 10.1185/03007995.2011.654109. Epub 2012 Jan 23. Curr Med Res Opin. 2012. PMID: 22208675

6

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

Clemens A, van Ryn J, Sennewald R, Yamamura N, Stangier J, Feuring M, Härtter S. Clemens A, et al. Among authors: stangier j. Eur J Clin Pharmacol. 2012 May;68(5):607-16. doi: 10.1007/s00228-011-1205-2. Epub 2012 Jan 18. Eur J Clin Pharmacol. 2012. PMID: 22252796 Free PMC article. Clinical Trial.

7

Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.

Ring A, Rathgen K, Stangier J, Reilly P, Clemens A, Friedman J. Ring A, et al. Among authors: stangier j. Clin Drug Investig. 2013 May;33(5):333-42. doi: 10.1007/s40261-013-0058-0. Clin Drug Investig. 2013. PMID: 23519576 Free PMC article. Clinical Trial.

8

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. Stangier J, et al. Br J Clin Pharmacol. 2007 Sep;64(3):292-303. doi: 10.1111/j.1365-2125.2007.02899.x. Epub 2007 May 15. Br J Clin Pharmacol. 2007. PMID: 17506785 Free PMC article. Clinical Trial.

9

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

Stangier J, Stähle H, Rathgen K, Fuhr R. Stangier J, et al. Clin Pharmacokinet. 2008;47(1):47-59. doi: 10.2165/00003088-200847010-00005. Clin Pharmacokinet. 2008. PMID: 18076218 Clinical Trial.

10

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

Stangier J. Stangier J. Clin Pharmacokinet. 2008;47(5):285-95. doi: 10.2165/00003088-200847050-00001. Clin Pharmacokinet. 2008. PMID: 18399711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters